Leon Moulder, Jr. Acquires 57,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. bought 57,000 shares of the stock in a transaction on Monday, February 2nd. The stock was purchased at an average price of $17.96 per share, for a total transaction of $1,023,720.00. Following the purchase, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. This represents a 15.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Zenas BioPharma Stock Up 4.8%

ZBIO opened at $20.66 on Thursday. The company has a market capitalization of $1.11 billion, a PE ratio of -2.92 and a beta of -1.50. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. Zenas BioPharma, Inc. has a fifty-two week low of $6.11 and a fifty-two week high of $44.60. The business has a 50-day moving average of $29.61 and a 200-day moving average of $25.27.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Key Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO insider purchase — Leon Moulder Jr. bought 57,000 shares at about $17.96 (≈$1.02M), increasing his stake to ~423,155 shares (a 15.6% rise in his holdings). Insider buying of this size is a strong bullish signal for investors. InsiderTrades: CEO Purchases 57,000 Shares
• Positive Sentiment: Upcoming investor event — Zenas management will present at the Guggenheim Emerging Outlook: Biotech Summit on Feb. 11, which could drive additional analyst/investor attention and act as a catalyst if management provides encouraging clinical or commercial updates. GlobeNewsWire: Guggenheim Presentation
• Positive Sentiment: Analyst sentiment leans constructive — the consensus is a “Moderate Buy” with a materially higher average target than current levels, supporting upside expectations from some sell‑side firms. This helps underpin buying interest. AmericanBankingNews: Moderate Buy Consensus
• Neutral Sentiment: Relative price strength is rising — coverage noted ZBIO’s improving technical momentum (RPS), which can attract momentum traders but doesn’t guarantee fundamental progress. MSN: Rising Relative Price Strength
• Neutral Sentiment: Market write‑ups explaining the jump — recent articles (AAII, MarketBeat summaries) attribute the rally largely to the CEO buy and renewed positive attention; useful for context but not new catalysts by themselves. AAII: Why ZBIO Is Up
• Negative Sentiment: Investor litigation inquiry — Pomerantz LLP has opened an investigation into Zenas, which introduces legal and reputational risk that could pressure the stock if it develops. Monitor filings and potential developments. GlobeNewsWire: Pomerantz Investor Alert
• Negative Sentiment: Recent earnings history — Zenas reported a notable quarterly EPS miss on Nov. 12 (loss per share larger than consensus), a reminder that underlying fundamentals and trial/readout execution remain key risk factors. MarketBeat: Earnings and Financials

Wall Street Analyst Weigh In

ZBIO has been the subject of a number of recent research reports. Morgan Stanley cut shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $37.00 to $19.00 in a report on Monday, January 5th. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Tuesday, December 16th. Evercore ISI began coverage on Zenas BioPharma in a research note on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a research report on Monday, December 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.14.

Institutional Trading of Zenas BioPharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in shares of Zenas BioPharma during the fourth quarter worth approximately $38,000. Quarry LP increased its position in Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares during the period. Russell Investments Group Ltd. acquired a new position in Zenas BioPharma during the 3rd quarter valued at $30,000. CWM LLC raised its stake in Zenas BioPharma by 48.3% during the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Zenas BioPharma in the 4th quarter valued at $95,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.